Avagacestat

Avagacestat is a research drug designed to target and inhibit an enzyme called gamma-secretase, which is involved in producing amyloid beta peptides linked to Alzheimer’s disease. By blocking this enzyme, avagacestat aims to reduce the formation of amyloid plaques in the brain, potentially slowing the progression of Alzheimer’s. Although it showed promise in early studies, clinical trials faced challenges related to side effects and effectiveness, and it is not currently approved for widespread use. Its development has contributed to understanding how targeting specific enzymes might help treat neurodegenerative conditions.